Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Autologous CD19 CAR-T”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT03564977
What this trial is testing

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Who this might be right for
Lymphoma, B-CellLeukemia, B-CellMinimal Disease, Residual
Qingdao Central Hospital 20
Early research (Phase 1)Active Not RecruitingNCT03620058
What this trial is testing

CART22 Alone or in Combination With huCART19 for ALL

Who this might be right for
Chemotherapy Resistant Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
University of Pennsylvania 23
Early research (Phase 1)Looking for participantsNCT05010564
What this trial is testing

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

Who this might be right for
Leukemia, B-Cell
Baylor College of Medicine 38
Early research (Phase 1)Active Not RecruitingNCT05797233
What this trial is testing

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic LeukemiaLymphoma, B-Cell
National Cancer Institute (NCI) 58
Early research (Phase 1)UnknownNCT05640713
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Henan Cancer Hospital 12
Testing effectiveness (Phase 2)Study completedNCT01747486
What this trial is testing

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Who this might be right for
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
University of Pennsylvania 42
Early research (Phase 1)Study completedNCT04450069
What this trial is testing

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell LymphomasDiffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more
Calibr, a division of Scripps Research 18
Testing effectiveness (Phase 2)Ended earlyNCT06400303
What this trial is testing

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Who this might be right for
Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Kyverna Therapeutics 3
Early research (Phase 1)UnknownNCT04037566
What this trial is testing

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Who this might be right for
Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-Cell+1 more
Xijing Hospital 40
Testing effectiveness (Phase 2)UnknownNCT02134262
What this trial is testing

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jichi Medical University 18
Early research (Phase 1)UnknownNCT03208556
What this trial is testing

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Peking University 20
Early research (Phase 1)UnknownNCT03685786
What this trial is testing

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

Who this might be right for
Leukemia, Lymphocytic, Acute, B-CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Shenzhen Second People's Hospital 20
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT07244406
What this trial is testing

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Who this might be right for
B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 59
Not applicableLooking for participantsNCT06503224
What this trial is testing

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
The First Affiliated Hospital of University of Science and Technology of China 18
Large-scale testing (Phase 3)Looking for participantsNCT07188558
What this trial is testing

Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Who this might be right for
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin Lymphoma+6 more
Lyell Immunopharma, Inc. 400
Very early researchNot Yet RecruitingNCT07277504
What this trial is testing

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command 50
Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Early research (Phase 1)Looking for participantsNCT07331467
What this trial is testing

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd 18
Testing effectiveness (Phase 2)Looking for participantsNCT04422912
What this trial is testing

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Who this might be right for
Pemphigus Vulgaris
Cabaletta Bio 40
Next Page